FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes
Metrics: HTML 1278 views | ?
Sebastien Rinaldetti1, Ralph Markus Wirtz2, Thomas Stefan Worst3, Markus Eckstein4, Cleo Aaron Weiss5, Johannes Breyer6, Wolfgang Otto6, Christian Bolenz7, Arndt Hartmann4 and Philipp Erben3
1Department of Hematology and Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany
2Stratifyer Molecular Pathology GmbH, 50935 Köln, Germany
3Department of Urology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany
4Institute of Pathology, University Erlangen-Nuremberg, 91054 Erlangen, Germany
5Institute of Pathology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany
6Department of Urology, University of Regensburg, 93053 Regensburg, Germany
7Department of Urology, University of Ulm, 89075 Ulm, Germany
Sebastien Rinaldetti, email: firstname.lastname@example.org
Keywords: FOXM1, muscle invasive bladder cancer, KI67, subclassification, survival prediction
Received: December 28, 2016 Accepted: April 10, 2017 Published: April 24, 2017
Forkhead box M1 (FOXM1) is a late cell cycle gene that plays a crucial role in carcinogenesis and chemotherapeutic drug resistance. In this study, the impact of FOXM1 expression on patient outcome was investigated for the first time in formalin fixed and paraffin embedded (FFPE) samples of chemotherapy naïve muscle-invasive bladder cancer (MIBC) patients. Expression analyses were performed on the Mannheim cohort (n=84) and validated on the independent Chungbuk cohort (n=61). In a Cox’ proportional hazards model, a distinct FOXM1 expression cut-off dividing both cohorts in a ‘high-risk’ and ‘low-risk’ group has been determined. Multivariate analyses showed that FOXM1 is an independent risk factor for outcome prediction superior to the TNM system. The FOXM1 ‘high-risk’ group had a 4- to 7-fold increased risk of death (p<0.03) and presented further an overexpression of MKI67. Recent studies showed that MIBCs can be subclassified in breast cancer-like subtypes: basal, luminal and p53-like. Here we demonstrated that FOXM1 was differentially expressed between MIBC subtypes concordant to its subtype specific expression in breast cancer. Since the proto-oncogene FOXM1 is known to play an important role in cisplatin resistance and to be a promising drug target, this study supports FOXM1 as a crucial biomarker in the personalization of MIBC therapy and urges prospective translational studies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.